	US 12,419,903 B1
	Compositions and methods of treatment for various conditions using high-molecular weight hyaluronic acid
Barry E. Rothenberg, Del Mar, CA (US)
Assigned to Embrient Inc., San Diego, CA (US)
Filed by Embrient, Inc., San Diego, CA (US)
Filed on Oct. 8, 2023, as Appl. No. 18/482,891.
Application 18/482,891 is a continuation in part of application No. 17/215,839, filed on Mar. 29, 2021, granted, now 11,780,871.
Claims priority of provisional application 63/005,136, filed on Apr. 3, 2020.
Int. Cl. A61K 31/728 (2006.01); A61K 35/19 (2015.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/728 (2013.01) [A61K 35/19 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01)]

11 Claims

1. A method of treatment of acute pancreatitis in a subject, comprising:

diagnosing that the acute pancreatitis is an M1 macrophage-driven inflammatory condition; and

within 7 days after diagnosis, parenterally administering to the subject a composition comprising a high molecular weight hyaluronic acid (HMW-HA) having a molecular weight of at least 1,000 kDa, and optionally further comprising platelet-rich plasma (PRP) and/or an anti-Stabilin-2 antibody,

wherein the composition is administered in an amount that induces M2 macrophage polarization and/or suppresses M1 macrophage activity.